health information
Posts tagged Pharmaceuticals
Access Pharmaceuticals Initiates U.S. MuGard sampling program with leading oncology groups
0Access Pharma Initiates US MuGard Sampling Program with Leading Oncology Groups DALLAS and NEW YORK, June 15 /PRNewswire-FirstCall/ — ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has initiated a broad-scale MuGard Centers-of-Excellence Sampling Program with leading oncology networks for its lead product, MuGard, a FDA-approved product for the management of …
Read more on redOrbit
Qivana team of McKesson Pharmaceuticals, Noni, Xango, Usana NuSkin and running?
01 year ago
by admin
in Health Care
According Prelaunch, Qivana by the former headmaster of McKesson Pharmaceuticals, and four former distributors of Tahitian Noni, Xango started, NuSkin and Usana.
After marketing pages posted on the company, launch is tentatively set for September or October 2009.
Who Cares?
You could, if your part Qivana, but other than that of the general public, or people who belong to other network marketing company simply pays no attention.
Why? People are busy with their own lives, and they are busy marketing their own products and services. In fact, most people are only to be simply not More >
Rexahn Pharmaceuticals to Initiate Zoraxel Phase IIb Trial for Treatment of Erectile Dysfunction
02 years ago
by admin
in Health Conditions
Rexahn Pharmaceuticals to Initiate Zoraxel Phase IIb Trial for Treatment of Erectile Dysfunction ROCKVILLE, Md.—-Rexahn Pharmaceuticals, Inc. , a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction .
Read more on Business Wire via Yahoo! Finance
Stellar Pharmaceuticals Inc. signed an agreement for the distribution and sale of Uracyst (R) in Germany and Austria
0Stellar Pharmaceuticals Inc. Signs Agreement for Distribution and Sale of Uracyst(R) in Germany and Austria Continued Expansion of Stellar’s Global Strategy
Read more on Marketwire
Stellar Pharmaceuticals signs licensing agreement for distribution and sale of Uracyst (R) in Portugal
0Stellar Pharmaceuticals Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Portugal LONDON, ONTARIO–(Marketwire – 05/05/10) – Stellar Pharmaceuticals Inc. (Stellar) (OTC.BB: SLXCF – News ), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing a licensing agreement for the distribution and sale of one of its lead products, Uracyst (a sterile sodium chondroitin sulfate solution, 2%) for …
Read more on Marketwire via Yahoo! Finance
Alvine Pharmaceuticals presents data on the effects of ALV003 in a gastric model, the in vivo activity Predicts at DDW. . .
0Alvine Pharmaceuticals Presents Data on the Effects of ALV003 in a Gastric Model That Predicts In Vivo Activity at DDW … SAN CARLOS, Calif.—-Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week meeting held in New Orleans, Louisiana.
Read more on Business Wire via Yahoo! Finance
OSI Pharmaceuticals Announces That “RADIANT”, an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung . . .
02 years ago
by admin
in Health Care
OSI Pharmaceuticals Announces That “RADIANT”, an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung … MELVILLE, N.Y.—-OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva® as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.
Read more on Business Wire via Yahoo! Finance
